TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32778081

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using inclinometer for seated and standing upper thoracic spine posture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using measuring tape for TS posture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability assessment using manual assessment for segmental extension
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using inclinometer for standing and seated upper TS posture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment using inclinometer for standing whole TS posture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison of intra-rater and inter-rater reliability
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reliability of posture measurements with an inclinometer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reliability of manual assessments
Number of subjects: 32
Study: 32778095

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg BID followed by olaparib + durvalumab (1500 mg Q4W) + tremelimumab (75 mg IV Q4W) for 4 months, then durvalumab alone until progression or intolerable toxicity.
Number of subjects: 213
Study: 32778118

Group type: EXPERIMENTAL
Intervention: Mollii® suit used for 6 weeks
Number of subjects: 20
Study: 32778146

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-Dexmedetomidine (non-DEX)
Number of subjects: 201
Study: 32778555

Group type: EXPERIMENTAL
Intervention: Health care coverage in states with expanded Medicaid
Number of subjects: 0

Group type: COMPARATOR
Intervention: No health care coverage
Number of subjects: 0
Study: 32778748

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 0
Study: 32778827

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 56
Study: 32778912

Group type: EXPERIMENTAL
Intervention: Systematic biopsy (SBx) in addition to targeted biopsy (TBx)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Nomogram based on MRI volumetric parameters and clinical information
Number of subjects: 384
Study: 32779037

Group type: EXPERIMENTAL
Intervention: Prior neoadjuvant/adjuvant trastuzumab (NAT)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: De novo MBC patients
Number of subjects: 287
Study: 32779077

Group type: EXPERIMENTAL
Intervention: Per-lesion level CCTA measures
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Per-patient level CCTA measures
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Model 1 (adjusted only by clinical risk factors)
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Comparison of per-lesion versus per-patient analysis
Number of subjects: 1297
Study: 32779571

Group type: EXPERIMENTAL
Intervention: Internet-based intervention (digital)
Number of subjects: 2909

Group type: EXPERIMENTAL
Intervention: Internet-based intervention with face-to-face group coaching (F2F+digital)
Number of subjects: 2909

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 2909
Study: 32779573

Group type: EXPERIMENTAL
Intervention: SMART program (stepped-care eHealth HIV prevention program)
Number of subjects: 1285
Study: 32779705

Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Number of subjects: 12
Study: 32779730

Group type: COMPARATOR
Intervention: Targeted client communication via mobile devices (TCCMD)
Number of subjects: 26854
Study: 32779863

Group type: EXPERIMENTAL
Intervention: Anakinra (subcutaneous daily injections starting at 2 mg/kg, increased up to 6 mg/kg if fever persisted)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 16
Study: 32779947

Group type: EXPERIMENTAL
Intervention: MRD monitored at days 33 and 90
Number of subjects: 0
Study: 32780021

Group type: EXPERIMENTAL
Intervention: Computer debriefing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no debriefing)
Number of subjects: 28
Study: 32780026

Group type: EXPERIMENTAL
Intervention: BPTrack intervention (clinical pharmacist-led mobile health approach)
Number of subjects: 15
Study: 32780519

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study: 32780600

Group type: EXPERIMENTAL
Intervention: High-frequency vital-sign monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 0
Study: 32780661

Group type: EXPERIMENTAL
Intervention: HFRT (43.5 Gy in 15 fractions over 3 weeks with a boost of 8.7 Gy in three daily fractions)
Number of subjects: 734

Group type: COMPARATOR
Intervention: CFRT (50 Gy in 25 fractions over 5 weeks with a boost of 10 Gy in five fractions over 1 week)
Number of subjects: 734
Study: 32780660

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 275
Study: 32780725

Group type: EXPERIMENTAL
Intervention: Sleeping Beauty-engineered CAR T cells
Number of subjects: 13
Study: 32780845

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 187
Study: 32780846

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel, CD19-28z CAR T therapy, B-cell maturation antigen targeting CAR T cells)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 83
Study: 32780964

Group type: EXPERIMENTAL
Intervention: Low-frequency extension (LFE) setting
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal setting
Number of subjects: 42
Study: 32780981

Group type: EXPERIMENTAL
Intervention: Walking training using a novel assistive gait training device, 3 sessions a week for 8 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Walking training using a novel assistive gait training device
Number of subjects: 11
Study: 32781244

Group type: EXPERIMENTAL
Intervention: Derivation cohort (n=644)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=469)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Risk factors for SRF in derivation cohort
Number of subjects: 1113
Study: 32781287

Group type: EXPERIMENTAL
Intervention: Driving distance (operationalized as a continuous variable)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Driving distance (operationalized as a dichotomous variable: <100 miles vs 100+ miles)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host-disease
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Lack of Internet access
Number of subjects: 1136
Study: 32781286

Group type: EXPERIMENTAL
Intervention: Support, Educate, Empower (SEE) personalized glaucoma coaching program
Number of subjects: 39
Study: 32781527

Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitor of fibroblast growth factor receptor 2 (FGFR2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapeutic drugs
Number of subjects: 0
Study: 32781541

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus IT-MTX (intrathecal methotrexate) 12 mg, six cycles of R-CHOP and four fixed doses of IT-MTX.
Number of subjects: 33
Study: 32781883

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the 8-Item Patient Health Questionnaire (score ≥10 indicating clinically relevant depressive symptoms) at baseline and 3 months.
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Health status measured by Peripheral Artery Questionnaire and EQ-5D Visual Analogue Scale at baseline and 3, 6, and 12 months.
Number of subjects: 1243
Study: 32782084

Group type: EXPERIMENTAL
Intervention: Amphetamine-type stimulant positive patients
Number of subjects: 396

Group type: COMPARATOR
Intervention: Amphetamine-type stimulant negative patients
Number of subjects: 396
Study: 32782818

Group type: EXPERIMENTAL
Intervention: Pediatric size phlebotomy tubes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Adult size phlebotomy tubes
Number of subjects: 200
Study: 32785569

Group type: EXPERIMENTAL
Intervention: Rocuronium during volatile anesthesia (Group I)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No muscle relaxant during volatile anesthesia (Group II)
Number of subjects: 126
Study: 32785680

Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-pyruvate magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4+ T effector memory cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-cell sequencing of circulating T cells
Number of subjects: 0
Study: 32785820

Group type: EXPERIMENTAL
Intervention: Longitudinal tau accumulation in MCI subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MRI atrophy in MCI subjects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Longitudinal FTP accumulation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline FTP uptake
Number of subjects: 23
Study: 32785881

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam
Number of subjects: 340

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 340
Study: 32786149

Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Number of subjects: 88

Group type: COMPARATOR
Intervention: Corticosteroids and/or tacrolimus treatment for rejection
Number of subjects: 88
Study: 32787449

Group type: EXPERIMENTAL
Intervention: palbociclib
Number of subjects: 0
Study: 32787797

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients (various treatments: RP, EBRT, HIFU, CT, ADT, AS)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients
Number of subjects: 819
Study: 32787913

Group type: EXPERIMENTAL
Intervention: Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 32
Study: 32788120

Group type: EXPERIMENTAL
Intervention: Individualised thromboprophylaxis protocol with augmented LMWH dosing, anti-Xa measurements, and twice-weekly ultrasonography screening for DVT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Individualised thromboprophylaxis protocol
Number of subjects: 72
Study: 32788149

Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: WebApp
Number of subjects: 250

Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 250
Study: 32788205

Group type: EXPERIMENTAL
Intervention: TAK-164 (a second-generation investigational antibody-drug conjugate comprised of a human anti-GCC mAb conjugated to DGN549)
Number of subjects: 0
Study: 32788687

Group type: EXPERIMENTAL
Intervention: E2 treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: E2 withdrawal (E2-WD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vehicle baseline
Number of subjects: 17
Study: 32788708

Group type: EXPERIMENTAL
Intervention: Type I interferon treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 32789526

Group type: EXPERIMENTAL
Intervention: Photoreceptor-related imaging features (ONL, IS, OS thickness)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Photoreceptor-related imaging features (OS thickness)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) loss-to-GA boundary distance
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fully automated B-scan segmentation
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Macula-wide photoreceptor laminae thinning
Number of subjects: 89
Study: 32789591

Group type: EXPERIMENTAL
Intervention: Single-agent abemaciclib
Number of subjects: 281

Group type: COMPARATOR
Intervention: Real-world single-agent chemotherapy (capecitabine, gemcitabine, eribulin, or vinorelbine)
Number of subjects: 281
Study: 32789800

Group type: EXPERIMENTAL
Intervention: Trabecular micro-bypass stent(s) implantation (iStent or iStent inject) with phacoemulsification
Number of subjects: 47
Study: 32789967

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally once daily
Number of subjects: 35
Study: 32790018

Group type: EXPERIMENTAL
Intervention: De novo novel missense variants in RPS20
Number of subjects: 2
Study: 32790648

Group type: EXPERIMENTAL
Intervention: Oral nicotinamide riboside (NR) for 5 to 9 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: MitoDAMP-treated PBMCs
Number of subjects: 19
Study: 32790733

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine alone
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine with azithromycin
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Neither drug
Number of subjects: 2512
Study: 32791124

Group type: EXPERIMENTAL
Intervention: 0.5 g of conjugated estrogen (Premarin cream) twice weekly for 12 weeks
Number of subjects: 0
Study: 32791158

Group type: EXPERIMENTAL
Intervention: Injection pressure monitoring during PNB
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intraneural needle tip location
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High flow rate (9.6 mL/min)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cervical roots (intraneural)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall injection pressure monitoring
Number of subjects: 37
Study: 32791423

Group type: EXPERIMENTAL
Intervention: APOE-ε4 homozygotes
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: CMBs
Number of subjects: 564
Study: 32791523

Group type: EXPERIMENTAL
Intervention: INSTI as a third agent
Number of subjects: 19462

Group type: COMPARATOR
Intervention: NNRTI or PI
Number of subjects: 19462
Study: 32791715

Group type: EXPERIMENTAL
Intervention: Functional near infrared spectroscopy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Moxibustion in the Heart meridian
Number of subjects: 120

Group type: COMPARATOR
Intervention: Moxibustion in the Lung meridian
Number of subjects: 120
Study: 32791868

Group type: EXPERIMENTAL
Intervention: 3D optical surface imaging
Number of subjects: 19
Study: 32792226

Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 10, 30, or 100 mg every other week for 38 weeks (n=6 per cohort)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg (cohort 4, n=6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg
Number of subjects: 24
Study: 32792335

Group type: EXPERIMENTAL
Intervention: Mass screening and eradication
Number of subjects: 7616
Study: 32792350

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Other types of imaging
Number of subjects: 1493

Group type: COMPARATOR
Intervention: No imaging reported
Number of subjects: 1493
Study: 32792421

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 0
Study: 32792436

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 462
Study: 32792456

Group type: EXPERIMENTAL
Intervention: Music therapy Sensory Instrument for Cognition, Consciousness and Awareness (MuSICCA)
Number of subjects: 80
Study: 32792659

Group type: EXPERIMENTAL
Intervention: UBE3A pathogenic variants and imprinting defects (IPD)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: UBE3A pathogenic variants (truncating mutations)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Deletion encompassing UBE3A and other genes
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Deletion length (class I vs. II)
Number of subjects: 250
Study: 32792991

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment after 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neurobiological response assessment using PET, fMRI, and EEG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Switch to duloxetine if non-response at week 4 or intolerable side effects
Number of subjects: 100
Study: 32793403

Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablets (FCT)
Number of subjects: 53
Study: 32793815

Group type: EXPERIMENTAL
Intervention: Scripts for discussing stopping cancer screening and information on patient's 10-year life expectancy provided to primary care providers (PCPs)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Scripts for discussing stopping cancer screening and information on patient's 10-year life expectancy provided to PCPs
Number of subjects: 90
Study: 32793850

Group type: EXPERIMENTAL
Intervention: Food insecurity (FI)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Marginal food security
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Food insecurity (FI) with meal plans (MP)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Food security (FS) with meal plans (MP)
Number of subjects: 683
Study: 32794142

Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (0.5-2.0 mg/kg)
Number of subjects: 22
Study: 32794560

Group type: EXPERIMENTAL
Intervention: Biomarkers of severe RSV ARTI
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Biomarkers associated with respiratory sequelae
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Characterization of viral load and host immune response
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Transcriptomic, proteomic, metabolomic and epigenetic signatures
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Symptom severity scores
Number of subjects: 630
Study: 32794574

Group type: EXPERIMENTAL
Intervention: RSV associated hospitalization in the first year of life
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Active cohort of 1000 infants
Number of subjects: 10000
Study: 32795224

Group type: EXPERIMENTAL
Intervention: Obinutuzumab, Ibrutinib, and Venetoclax
Number of subjects: 50
Study: 32795349

Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx (200 mg IV of sintilimab and 1000 mg/m2 of capecitabine and oxaliplatin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx
Number of subjects: 20
Study: 32795990

Group type: EXPERIMENTAL
Intervention: PromMera app intervention for 12 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 154
Study: 32795996

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titrated CPAP pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysomnography and bronchoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest computed tomography
Number of subjects: 0
Study: 32796254

Group type: EXPERIMENTAL
Intervention: Cycling exercise (65% V˙O2max) for 1 hour
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary (rest)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cycling exercise (65% V˙O2max)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 14
Study: 32796418

Group type: EXPERIMENTAL
Intervention: Runners who suffered EAMC
Number of subjects: 98
Study: 32797064

Group type: EXPERIMENTAL
Intervention: Non-compacted LV mass (median 14.0 [interquartile range 12.6-16.0] g/m2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ratio of non-compacted to compacted LV mass (mean 25.6 ± 4.2%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percentage of non-compacted LV volume (mean 17.6 ± 2.9%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percentage of non-compacted LV volume
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of right-to-left shunt (RLS)
Number of subjects: 60
Study: 32797101

Group type: EXPERIMENTAL
Intervention: Mass drug administrations (MDAs) and reactive focal mass drug administrations (rfMDAs) with annual indoor residual spraying (IRS) and long-lasting insecticidal nets (LLINs)
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Mass drug administrations (MDAs)
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Phase I interventions
Number of subjects: 48448

Group type: EXPERIMENTAL
Intervention: Overall project interventions
Number of subjects: 48448
Study: 32797734

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 3305
Study: 32798130

Group type: EXPERIMENTAL
Intervention: Giant CAMLs present at T3 (30 days after CRT completion)
Number of subjects: 39
Study: 32798473

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with haematological malignancies
Number of subjects: 536
Study: 32798522

Group type: EXPERIMENTAL
Intervention: Patients with SDB
Number of subjects: 250

Group type: COMPARATOR
Intervention: Patients without SDB
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Central Sleep Apnea (CSA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: History of transient ischemic attack or stroke
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Patients with postoperative MPCs
Number of subjects: 250
Study: 32798585

Group type: EXPERIMENTAL
Intervention: HIV/HCV-coinfected
Number of subjects: 2641

Group type: COMPARATOR
Intervention: HCV-monoinfected
Number of subjects: 2641
Study: 32799036

Group type: EXPERIMENTAL
Intervention: Imatinib treatment in frontline therapy
Number of subjects: 339
Study: 32799072

Group type: EXPERIMENTAL
Intervention: Slow habituation phenotype
Number of subjects: 229

Group type: COMPARATOR
Intervention: Rapid habituation phenotype
Number of subjects: 229
Study: 32799356

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 718

Group type: COMPARATOR
Intervention: Extended duration antibiotics
Number of subjects: 718

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 718
Study: 32799568

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0
Study: 32799695

Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Predominant Breastfeeding (PBF)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Partial Breastfeeding (PartBF)
Number of subjects: 110